As­traZeneca gets an ear­ly green light on BTK block­buster hope­ful Calquence

Im­age: Pas­cal So­ri­ot AP Im­ages

As­traZeneca $AZN has re­ceived an ear­ly OK from reg­u­la­tors to sell its can­cer drug acal­abru­ti­nib, now un­der the brand name Calquence.

The BTK in­hibitor — be­ing set up as a ri­val to Im­bru­vi­ca from Ab­b­Vie and J&J — is a treat­ment for can­cer pa­tients with man­tle cell lym­phoma, a rare B-cell non-Hodgkin lym­phoma. The drug will be used as a sec­ond-line ther­a­py for re­lapsed/re­frac­to­ry man­tle cell lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.